Sinsinbar Gaurav, Bindra Anivind Kaur, Liu Shaoqiong, Chia Teck Wan, Yoong Eng Eunice Chia, Loo Ser Yue, Lam Jian Hang, Schultheis Katherine, Nallani Madhavan
ACM Biolabs Pte Ltd., 71 Nanyang Drive, #02M-02, NTU Innovation Center, Singapore 638075, Singapore.
Biomacromolecules. 2024 Feb 12;25(2):541-563. doi: 10.1021/acs.biomac.3c00858. Epub 2024 Jan 19.
Nanoformulation of active payloads or pharmaceutical ingredients (APIs) has always been an area of interest to achieve targeted, sustained, and efficacious delivery. Various delivery platforms have been explored, but loading and delivery of APIs have been challenging because of the chemical and structural properties of these molecules. Polymersomes made from amphiphilic block copolymers (ABCPs) have shown enormous promise as a tunable API delivery platform and confer multifold advantages over lipid-based systems. For example, a COVID booster vaccine comprising polymersomes encapsulating spike protein (ACM-001) has recently completed a Phase I clinical trial and provides a case for developing safe drug products based on ABCP delivery platforms. However, several limitations need to be resolved before they can reach their full potential. In this Perspective, we would like to highlight such aspects requiring further development for translating an ABCP-based delivery platform from a proof of concept to a viable commercial product.
活性载荷或药物成分（API）的纳米制剂一直是实现靶向、持续和有效递送的一个备受关注的领域。人们已经探索了各种递送平台，但由于这些分子的化学和结构特性，API的负载和递送一直具有挑战性。由两亲性嵌段共聚物（ABCP）制成的聚合物囊泡作为一种可调节的API递送平台显示出巨大的潜力，并且比基于脂质的系统具有多重优势。例如，一种包含包裹刺突蛋白的聚合物囊泡的新冠加强疫苗（ACM-001）最近完成了I期临床试验，并为基于ABCP递送平台开发安全的药品提供了一个实例。然而，在它们发挥全部潜力之前，还有几个限制需要解决。在本观点文章中，我们想强调将基于ABCP的递送平台从概念验证转化为可行的商业产品所需进一步发展的此类方面。
